The US Food and Drug Administration (FDA) approved Panzyga, manufactured by Octapharma AG, for the treatment of PI and ITP in 2018 and for CIDP in adults in 2021. Octapharma commercializes Panzyga ...

The prognosis of spinal muscular atrophy (SMA) depends on many factors, including disease type and severity, age at symptom onset, SMN2 gene copy number, genetic modifiers, and the therapeutic support ...